Cytokinetics showcases Five Aficamten presentations at ESC Congress 2025

Cytokinetics, Incorporated (announced five presentations related to aficamten at the European Society of Cardiology Congress 2025 taking place in Madrid, Spain from August 29, 2025 – September 1, 2025 including a Hot Line presentation of the primary results from MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM) and a Late Breaking Clinical Science presentation relating to the incidence and impact of atrial fibrillation across three clinical trials of aficamten in obstructive hypertrophic cardiomyopathy (HCM).
Oral Presentations
Title: MAPLE-HCM: Aficamten vs Metoprolol in Obstructive HCM
Presenter: Pablo Garcia-Pavia, M.D., Ph.D., Head of the Inherited Cardiac Diseases and Heart Failure Unit, Department of Cardiology, Hospital Universitario Puerta de Hierro and Full Professor, Centro Nacional de Investigaciones Cardiovasculares both in Madrid, Spain
Date: August 30, 2025
Session Title: Hot Line 2
Session Time: 8:15 – 9:45 AM CEST
Presentation Time: 9:18 AM CEST
Location: Madrid (Main Auditorium)
Title: REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM Trials: Incidence and Impact of Atrial Fibrillation in Obstructive HCM with Aficamten
Presenter: Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University
Date: August 31, 2025
Session Title: Late-Breaking Clinical Science: Cardiomyopathies
Session Time: 4:15-5:15 PM CEST
Presentation Time: 4:45 PM CEST
Location: Budapest (Hall 10)
Title: Efficacy and Safety of Long-Term Treatment with Aficamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results from FOREST-HCM
Presenter: Sara Saberi, M.D., M.S., Associate Professor of Internal Medicine, University of Michigan Health Frankel Cardiovascular Center
Date: August 31, 2025
Session Title: Hypertrophic Cardiomyopathy: From Gene to Treatment
Session Time: 5:00 – 6:00 PM CEST
Presentation Time: 5:40 PM CEST
Location: Science Box 4 (Research Gateway)
Poster Presentations
Title: Effect of Aficamten Compared with Metoprolol on Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Pre-Specified Analysis of MAPLE-HCM
Presenter: Sheila Hegde, M.D., M.P.H, Assistant Professor, UT Southwestern Medical Center, Dallas, TX, Affiliate Faculty, Brigham and Women’s Hospital, Boston, MA
Final presentation date and time to be confirmed
Title: Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy: An Integrated Safety Analysis
Presenter: Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University
Final presentation date and time to be confirmed